Stock Ratings / Health Care / CTXR / options

NCEL (39) JAGX (31) OPTH (49) RADX (61) ⌘ Pro Terminal →

Citius Pharmaceuticals Inc. (CTXR) Options Positioning, Max Pain & Unusual Sweeps

$0.56 +4.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Citius Pharmaceuticals Inc. (CTXR) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $15.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTXR)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CTXR)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CTXR.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTXR)

✓Walkthrough of CTXR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CTXR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.00%📐 HORIZONTAL RANGE

2026-10-30O $0.56H $0.56L $0.52C $0.56VOL 99.6K

RES: $0.92SUP: $0.35SMA50: $0.54SMA200: $0.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTXR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTXR Butterfly Map → + Track CTXR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CTXR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTXR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CTXR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTXR)

Health Care Rank #368 of 1016 ⚔️ NCEL vs CTXR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTXR vs. NCEL, JAGX, OPTH, RADX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Citius Pharmaceuticals Inc. (CTXR) ranks #368 by composite RQD confidence (49/100, grade D) and #858 by equity capitalization ($15.5M). Within this direct 5-issuer industry benchmark cohort, CTXR leads on earnings valuation at N/A trailing P/E, while CTXR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RADX currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with CTXR at 49/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CTXR ACTIVE Citius Pharmaceuticals Inc.	D	49/100	—	—	-35.0%	+4.07%	$15.5M	Benchmark Subject
NCEL NewcelX Ltd.	D-	39/100	—	—	-35.0%	-0.30%	$15.5M	/ncel-vs-ctxr →
JAGX Jaguar Health Inc.	E	31/100	—	67.2%	-35.0%	-2.86%	$15.9M	/jagx-vs-ctxr →
OPTH Optimi Health Corp.	D	49/100	—	—	—	-6.81%	$14.9M	/opth-vs-ctxr →
RADX Radiopharm Theranostics Limited	C-	61/100	—	—	—	+17.52%	$16.1M	/radx-vs-ctxr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001506251

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Citius Pharmaceuticals Inc. (CTXR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $0, operating cash flow of -$26.6M, and free cash flow of -$26.6M (+5.8% YoY). On the balance sheet, CTXR closed FY2025 with $140.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$0	$0	-$26.6M	-$26.6M	$140.4M	—
FY2024 (FY)	2024-09-30	$0	$0	-$28.2M	-$28.2M	$120.7M	—
FY2023 (FY)	2023-09-30	$0	-$32.5M	-$29.1M	-$29.1M	—	—

3. CTXR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTXR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $0.56 (+4.07% 1D, market cap $15.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CTXR ranks #368 in composite RQD confidence.

How does CTXR compare to NCEL and JAGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTXR carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NCEL (NewcelX Ltd.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $15.5M) and JAGX (Jaguar Health Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.9M). Among the 5-stock peer group, CTXR leads on earnings multiple (N/A) while CTXR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTXR?

Per CTXR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001506251), Citius Pharmaceuticals Inc. generated $0 in revenue, $0 in net income, and -$26.6M in free cash flow against $140.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTXR trading relative to its 50-day, 200-day, and 52-week technical levels?

CTXR last traded at $0.56 (+4.07% on volume of 403,040 shares), positioning the stock +3.70% above its 50-day simple moving average ($0.54) and -15.15% below its 200-day simple moving average ($0.66). Across its 52-week range of $0.37 to $1.60, CTXR sits at the 15.4% percentile with a 14-day RSI of 53.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.63).

CTXR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CTXR's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CTXR.

Direct Sub-Reports: CTXR RQD Cockpit CTXR 12M Forecast CTXR Earnings & Move CTXR Dividends & DRIP CTXR Insiders & 13F CTXR Whale Options CTXR Profit Sankey CTXR News & Why